Perinatal infections: prevention of long-term sequelae
Related Experiment Videos
Insights
Preventing central nervous system infections in newborns is crucial. This research reviews key perinatal pathogens and discusses promising prevention strategies, including new cytomegalovirus vaccines.
Area of Science:
- Infectious Diseases
- Neurology
- Vaccinology
Background:
- Congenital, natal, and postnatal infections frequently cause central nervous system (CNS) disease and long-term sequelae.
- Key perinatal pathogens include group B Streptococcus, Escherichia coli, cytomegalovirus (CMV), Toxoplasma gondii, and herpes simplex virus.
- These pathogens pose significant threats to infant neurological health.
Purpose of the Study:
- To review important perinatal pathogens causing CNS infections.
- To discuss current and emerging strategies for preventing these infections.
- To evaluate the progress of cytomegalovirus (CMV) vaccine development.
Main Methods:
- Literature review of perinatal infections and CNS sequelae.
- Analysis of epidemiological data on key pathogens.
- Detailed examination of recent clinical trials for CMV vaccines (Towne 125 and AD 169).
Main Results:
- Several pathogens are identified as primary causes of CNS infections in neonates.
- Active research is yielding promising prevention strategies.
- Clinical trials for two CMV vaccines show potential for future prevention.
Conclusions:
- Effective prevention of perinatal CNS infections is achievable through targeted strategies.
- Vaccination, particularly against CMV, represents a significant advancement.
- Continued research and implementation of preventive measures are vital for reducing long-term neurological damage.
Abstract:
All the congenital infections and most of the natal and postnatally acquired infections of man are associated with disease of the central nervous system and long-term sequelae in the survivors. The most important perinatal pathogens in this regard are group B streptococcus, Escherichia coli and other coliform bacteria, cytomegalovirus, Toxoplasma gondii and herpes simplex virus. All these agents are the subject of active and, in some instances, promising investigation. The strategies for prevention are discussed here. Recent clinical trails of two cytomegalovirus vaccines (Towne 125 and AD 169) are considered in detail.